$ILMN

Leckman Patricia sold $28K of ILMN

Leckman Patricia (SVP, Chief People Officer) sold 176 shares of ILLUMINA, INC. (ILMN) at $160.66 on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Leckman Patricia
Published Jun 4, 2026, 8:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ILMN
Neutral
high confidence
Mentioned
$ILMN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not constitute new company-specific fundamental news.

02

Market read

Routine 10b5-1 insider selling is generally not a standalone catalyst for ILMN price action.

03

What to watch

Insider sales can be driven by diversification, taxes, or scheduled liquidity needs; without additional filings (buys, large sales, or plan changes), signal strength is limited.

Relevance 6/10Novelty 2/10Timing: Filed after-hours (SEC EDGAR) for a sale dated 2026-06-02.

Background

SEC Form 4 reports insider transactions; a 10b5-1 plan indicates the trades were pre-scheduled to reduce timing-based trading concerns.

Company-level read

Ticker impact

$ILMNNeutralHigh confidence
Context

Illumina insider disclosure shows SVP Chief People Officer Patricia Leckman sold 176 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely noise unless paired with other catalysts.

Evidence & confidence

Form 4 details a small, planned sale (176 shares) with no accompanying corporate event, guidance change, or transaction terms beyond standard 10b5-1 disclosure.

Market effects

No clear read-through to biotech/genomics sector fundamentals from a routine planned insider sale.

None.

None.

Counterpoint

If insider sales cluster unusually around specific dates, traders sometimes treat it as a weak sentiment signal; this single small 10b5-1 sale alone is not enough.

Key entities

  • Illumina, Inc.

    Subject of the Form 4 insider transaction; SVP Chief People Officer sold shares under a 10b5-1 plan.

  • Patricia Leckman

    SVP, Chief People Officer; reported open-market sale of 176 shares on 2026-06-02.

Related articles

$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Illumina (ILMN) reported Q2 2026 revenue of $1.16B, up 9.5% YoY, and non-GAAP EPS of $1.31. Clinical consumables and NovaSeq X placements drove results. Gross margin was 68.2%. Full-year 2026 guidance was raised to $4.60B-$4.64B revenue and $5.30-$5.40 EPS. Cash was $1.17B vs $1.99B debt.

$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Conor McNamara Chief Executive Officer - Jacob Thaysen Chief Financial Officer - Ankur Dhingra TAKEAWAYS Total Revenue -- $1.16 billion, representing a 9.5% increase year over year driven by clinical market demand and the NovaSeq X expansion. Rest of World Organic Revenue -- Increased 8.1% year over year, exceeding the high end of management's previous guidance.

$ILMNMedAI 8/10

Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full

Genomics company Illumina (NASDAQ: ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates. Is now the time to buy Illumina? Find out by accessing our full research report, it’s free.

$ILMNHigh

ILLUMINA, INC. (ILMN): Results of Operations and Financial Condition

ILLUMINA, INC. (ILMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226earningsrelease.htm EX-99.1 Document Investors: Conor McNamara +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 San Diego, July 30, 2026 /PRNewswire/ -- Illumina, Inc.